Loading
Life sciences · Journal article
Current Opinion in Clinical Nutrition & Metabolic Care · November 6, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
PURPOSE OF REVIEW: Sarcopenic obesity (SO) is increasingly recognized as a clinically relevant condition associated with functional impairment, cardiometabolic complications, disability and mortality. However, its diagnosis remains challenging because of heterogeneous definitions, uncertain thresholds, and limited accessibility of body composition assessment in routine clinical practice. This review summarizes recent advances and remaining challenges in the characterization and management of SO. RECENT FINDINGS: Recent studies have contributed to a better understanding of the epidemiology, clinical consequences and multifactorial pathophysiology of SO, highlighting the importance of muscle quality and the interplay between adipose tissue, skeletal muscle, immune, endocrine and metabolic pathways. Emerging approaches, including pragmatic functional screening tools, innovative phenotype index and artificial intelligence, may improve disease characterization and risk stratification, although further validation is needed. Multicomponent lifestyle interventions combining exercise and nutritional optimization remain the mainstay of management, while incretin-based therapies raise new questions regarding muscle preservation and weight cycling. SUMMARY: SO remains a heterogeneous and incompletely characterized condition. Progress toward clinical implementation will require greater harmonization of diagnostic approaches, validation of emerging tools, and intervention trials assessing muscle-related and patient-centred outcomes.